Bristol-Myers’ $560 million settlement is yet another success for its patent licensing campaign
AstraZeneca is the third Big Pharma company to pay BMS a nine-figure sum for the use of its immuno-oncology patents
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.